Enhancing cytotoxic T lymphocyte (CTL) responses by directly loading CTL epitope vaccines onto MHC Class I complexes on the dendritic cell surface
Enhancing cytotoxic T lymphocyte (CTL) responses by directly loading CTL epitope vaccines onto MHC Class I complexes on the dendritic cell surface
批准号:
9299648
负责人:
Mingnan Chen
金额:
$18.92万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-03-01 至 2018-12-31
关键词:
AlbuminsBindingBypassCancer VaccinesCell surfaceCellsClinicalComplexCytotoxic T-LymphocytesDataDefense MechanismsDendritic CellsDiseaseElastinElementsEngineeringEpitopesGelatinase AImmuneImmune responseImmunotherapyIn VitroInfectionInfection preventionLaboratoriesLymphLymphocyteLymphocyte ActivationMHC Class I GenesMalignant NeoplasmsMatrix MetalloproteinasesMediatingMethodsModelingMusOrganPatientsPeptidesPlayProcessProductionRecruitment ActivityResearchRoleSpleenTestingTherapeuticTherapeutic EffectVaccinationVaccine Clinical TrialVaccinesViral CancerVirus Diseasesbasecancer preventiondesignimprovedin vivolymph nodesmacromoleculemelanomanovelnovel vaccinespatient populationpolypeptideprophylacticpublic health relevanceresponsevaccination strategyvaccine deliveryvaccine developmentvaccine effectivenessvaccine efficacy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project summary
Cytotoxic T lymphocyte (CTL)-mediated immune responses are the primary effector mechanism in
immunotherapies against cancer and virus infection. Vaccines are able to boost CTL responses, and are being
intensively pursued in the laboratory and clinical settings. However, there is a large gap between the vaccine
development effort and the efficacy of these vaccines. This gap motivates us to reexamine current vaccination
strategies and to develop an alternative strategy to close the gap. Current strategies rely on the intra-dendritic
cell (DC) processing of vaccines, which is not efficient due to multiple barriers embedded in the process. We
thus aim to develop a distinct vaccination strategy that completely bypasses the intra-DC processing. To this
end, and based on our preliminary research results, we propose to develop an immune-tolerant elastin-like
polypeptide (iTEP)-based fusion as a vaccine carrier that is able to directly load CTL epitopes (CTL vaccines)
onto the MHC class I complexes on DC surfaces. These epitopes will be subsequently used by DCs to induce
CTL responses. We hypothesize that the fusion will drastically boost the effectiveness of the vaccines as
compared to vaccines requiring intra-DC processing. We will engineer and characterize the fusion with the
following two aims: Aim 1: Examine functionalities of the ABD-iTEP-pMMP-epitope fusion in vitro. Aim 2:
Establish functionalities and effects of the ABD-iTEP-pMMP-epitope fusion in vivo.
In consideration of the importance and current challenges of CTL vaccines, the main contribution of this
proposed study is that it explores a novel and a direct epitope loading strategy to unprecedentedly strengthen
CTL vaccine-induced responses. This novel yet straightforward strategy may bring about an unprecedented
impact on these vaccines, allowing them to play a more decisive role in the immunotherapy and immune
preventions of cancer, infections, and other diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeted depletion of programmed death-1 positive cells, a method that not only stops autoimmune attack but also preserves adaptive immunity
-
批准号:10321597
-
项目类别:
-
资助金额:$15.09万
-
财政年份:2019
-
负责人:Mingnan Chen
-
依托单位:
Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles
-
批准号:8704347
-
项目类别:
-
资助金额:$24.08万
-
财政年份:2012
-
负责人:Mingnan Chen
-
依托单位:
Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles
-
批准号:8518265
-
项目类别:
-
资助金额:$23.18万
-
财政年份:2012
-
负责人:Mingnan Chen
-
依托单位:
Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles
-
批准号:8476392
-
项目类别:
-
资助金额:$24.87万
-
财政年份:2012
-
负责人:Mingnan Chen
-
依托单位:
Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles
-
批准号:8133735
-
项目类别:
-
资助金额:$1.96万
-
财政年份:2010
-
负责人:Mingnan Chen
-
依托单位:
Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles
-
批准号:8420677
-
项目类别:
-
资助金额:$6.26万
-
财政年份:2010
-
负责人:Mingnan Chen
-
依托单位:
Inhibition of metastasis-initiating cells by chimeric polypeptide nanoparticles
-
批准号:8009726
-
项目类别:
-
资助金额:$8.07万
-
财政年份:2010
-
负责人:Mingnan Chen
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: